AR082577A1 - Vacunas de virus varicela zoster inactivado, metodos de produccion y uso de las mismas - Google Patents
Vacunas de virus varicela zoster inactivado, metodos de produccion y uso de las mismasInfo
- Publication number
- AR082577A1 AR082577A1 ARP110102849A ARP110102849A AR082577A1 AR 082577 A1 AR082577 A1 AR 082577A1 AR P110102849 A ARP110102849 A AR P110102849A AR P110102849 A ARP110102849 A AR P110102849A AR 082577 A1 AR082577 A1 AR 082577A1
- Authority
- AR
- Argentina
- Prior art keywords
- vzv
- inactivated
- virus
- same
- production methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La solicitud proporciona un virus varicela zóster (VVZ) inactivado, y composiciones y vacunas que comprenden dicho VVZ inactivado, donde la infectividad del VVZ es indetectable y donde el VVZ inactivado induce una respuesta inmune contra VVZ cuando se administra a un paciente. En realizaciones de las composiciones descritas en el presente documento, el VVZ se inactiva con radiación g. La solicitud también proporciona un método para preparar una vacuna de VVZ inactivado, comprendiendo el método someter a irradiación g una muestra que comprende VVZ usando de aproximadamente 5 kGy a aproximadamente 50 kGy de irradiación g. También se proporciona por la solicitud del presente documento un método de tratamiento o de inmunización contra HZ u otra enfermedad asociada con la reactivación de VVZ, comprendiendo el método administrar a un sujeto una vacuna o composición farmacéutica que comprende, una cantidad terapéuticamente eficaz de un VVZ inactivado y un vehículo farmacéuticamente aceptable, donde el VVZ se inactiva por irradiación g.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37103810P | 2010-08-05 | 2010-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082577A1 true AR082577A1 (es) | 2012-12-19 |
Family
ID=45556327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102849A AR082577A1 (es) | 2010-08-05 | 2011-08-05 | Vacunas de virus varicela zoster inactivado, metodos de produccion y uso de las mismas |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20120034267A1 (es) |
| EP (2) | EP3363894A1 (es) |
| JP (2) | JP2013535488A (es) |
| KR (3) | KR20130036062A (es) |
| CN (1) | CN103167880B (es) |
| AR (1) | AR082577A1 (es) |
| AU (1) | AU2011285749B2 (es) |
| BR (1) | BR112013001946A2 (es) |
| CA (1) | CA2806454A1 (es) |
| CL (2) | CL2013000360A1 (es) |
| CO (1) | CO6731067A2 (es) |
| EC (1) | ECSP13012476A (es) |
| MX (1) | MX343600B (es) |
| MY (1) | MY158419A (es) |
| NZ (1) | NZ606549A (es) |
| PE (1) | PE20131336A1 (es) |
| RU (1) | RU2633058C2 (es) |
| SG (1) | SG187222A1 (es) |
| TW (1) | TW201208698A (es) |
| UA (1) | UA112970C2 (es) |
| WO (1) | WO2012018973A1 (es) |
| ZA (1) | ZA201300622B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3041505A4 (en) | 2013-09-05 | 2017-04-19 | Merck Sharp & Dohme Corp. | Methods of immunization with varicella zoster virus antigen |
| RU2651040C2 (ru) * | 2016-08-08 | 2018-04-18 | Федеральное государственное бюджетное учреждение "48 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации | Вакцина оспенная инактивированная эмбриональная сухая таблетированная для орального применения "ТЭОВин" и способ ее получения |
| RU2637093C1 (ru) * | 2016-12-20 | 2017-11-29 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) | Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы |
| CN107174658B (zh) * | 2017-04-29 | 2020-11-27 | 安徽智飞龙科马生物制药有限公司 | 人用水痘病毒灭活疫苗及其制备方法 |
| CN109453371A (zh) * | 2018-11-23 | 2019-03-12 | 中国兽医药品监察所 | 一种羊痘、山羊传染性胸膜肺炎二联灭活疫苗及其生产方法 |
| RU2700410C1 (ru) * | 2019-05-20 | 2019-09-17 | Федеральное государственное бюджетное учреждение науки "Национальный научный центр морской биологии им. А.В. Жирмунского" Дальневосточного отделения Российской академии наук (ННЦМБ ДВО РАН) | Метод иммуноокрашивания биологического материала для конфокальной микроскопии |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5341202B2 (es) | 1974-03-12 | 1978-11-01 | ||
| DE2714665A1 (de) * | 1977-04-01 | 1978-10-05 | Mayr Anton | Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung |
| DE69331322T3 (de) * | 1992-07-17 | 2009-10-22 | Merck & Co., Inc. | Methode zur verhinderung von zoster und linderung der mit varicellea verbundenen postherpetischen neuralgie |
| US6022876A (en) * | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| AU2001263200A1 (en) * | 2000-05-17 | 2001-11-26 | The American National Red Cross | Gamma irradiation of protein-based pharmaceutical products |
| US6946098B2 (en) * | 2001-08-10 | 2005-09-20 | Clearant, Inc. | Methods for sterilizing biological materials |
| US20050175630A1 (en) * | 2003-12-23 | 2005-08-11 | Eyal Raz | Immunogenic compositions and methods of use thereof |
| WO2005085445A1 (ja) * | 2004-03-05 | 2005-09-15 | The Research Foundation For Microbial Diseases Of Osaka University | 組換え水痘帯状疱疹ウイルス |
| GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2733356C (en) | 2008-08-01 | 2016-06-07 | Gamma Vaccines Pty Limited | Influenza vaccines |
-
2011
- 2011-04-08 UA UAA201302742A patent/UA112970C2/uk unknown
- 2011-08-04 CN CN201180046512.6A patent/CN103167880B/zh not_active Expired - Fee Related
- 2011-08-04 AU AU2011285749A patent/AU2011285749B2/en not_active Ceased
- 2011-08-04 EP EP18160689.8A patent/EP3363894A1/en not_active Withdrawn
- 2011-08-04 US US13/198,191 patent/US20120034267A1/en not_active Abandoned
- 2011-08-04 KR KR1020137002903A patent/KR20130036062A/ko not_active Application Discontinuation
- 2011-08-04 TW TW100127807A patent/TW201208698A/zh unknown
- 2011-08-04 CA CA2806454A patent/CA2806454A1/en not_active Abandoned
- 2011-08-04 MY MYPI2013000290A patent/MY158419A/en unknown
- 2011-08-04 KR KR1020167013241A patent/KR20160060790A/ko not_active Application Discontinuation
- 2011-08-04 WO PCT/US2011/046534 patent/WO2012018973A1/en active Application Filing
- 2011-08-04 KR KR1020167002433A patent/KR20160018828A/ko not_active Application Discontinuation
- 2011-08-04 SG SG2013006515A patent/SG187222A1/en unknown
- 2011-08-04 JP JP2013523327A patent/JP2013535488A/ja active Pending
- 2011-08-04 BR BR112013001946A patent/BR112013001946A2/pt not_active IP Right Cessation
- 2011-08-04 RU RU2013109417A patent/RU2633058C2/ru not_active IP Right Cessation
- 2011-08-04 NZ NZ606549A patent/NZ606549A/en not_active IP Right Cessation
- 2011-08-04 EP EP11815299.0A patent/EP2600893A4/en not_active Ceased
- 2011-08-04 MX MX2013001434A patent/MX343600B/es active IP Right Grant
- 2011-08-04 PE PE2013000202A patent/PE20131336A1/es not_active Application Discontinuation
- 2011-08-05 AR ARP110102849A patent/AR082577A1/es unknown
-
2013
- 2013-01-23 ZA ZA2013/00622A patent/ZA201300622B/en unknown
- 2013-02-01 CO CO13019546A patent/CO6731067A2/es unknown
- 2013-02-05 CL CL2013000360A patent/CL2013000360A1/es unknown
- 2013-03-04 EC ECSP13012476 patent/ECSP13012476A/es unknown
-
2015
- 2015-04-03 US US14/678,542 patent/US20150209424A1/en not_active Abandoned
- 2015-10-02 JP JP2015196551A patent/JP2016053032A/ja active Pending
-
2016
- 2016-12-12 CL CL2016003181A patent/CL2016003181A1/es unknown
-
2018
- 2018-07-03 US US16/026,779 patent/US20180318412A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6731067A2 (es) | Vacunas de virus varicela zoster inactivado, métodos de producción y uso de las mismas | |
| JP5809560B2 (ja) | インフルエンザに対して使用するためのワクチン組成物 | |
| PE20170302A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
| ECSP14005678A (es) | Composiciones y métodos para tratar el virus de la hepatitis c | |
| BR112016004108A2 (pt) | métodos para expressar uma molécula antigênica ou uma parte da mesma e para geração de uma resposta imune, composição farmacêutica, célula ou população de células, usos de uma população de células e de uma molécula antigênica, moléculas antigênica, agentes de fotossensibilização e ligante tlr e agente, produto, e, kit | |
| BR112013009649A2 (pt) | composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição | |
| BRPI0720667A8 (pt) | Métodos de administração de vacina | |
| TR201908199T4 (tr) | HPV'ye karşı aşılar. | |
| KR20140033171A (ko) | 비활성화된 뎅기 바이러스 백신 | |
| Joyce et al. | Extended delivery of vaccines to the skin improves immune responses | |
| Garçon et al. | Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt | |
| BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
| Dong et al. | Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice | |
| AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
| BR112014023414A2 (pt) | vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos | |
| BR112013006515A2 (pt) | vacina de combinação, e, método para a fabricação de uma vacina de combinação | |
| BR112016002354A2 (pt) | composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit | |
| DiStefano et al. | Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques | |
| WO2010129947A3 (en) | Alpha thymosin peptides as vaccine enhancers | |
| EA201690057A1 (ru) | Остеопонтин молока млекопитающих для повышения иммунологической реактивности | |
| PE20110327A1 (es) | Vacuna contra el virus de papiloma humano | |
| Menon et al. | Laser-assisted intradermal delivery of a microparticle vaccine for respiratory syncytial virus induces a robust immune response | |
| MX2022004869A (es) | Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma. | |
| AR070368A2 (es) | Procedimiento para la preparacion de una composicion de vacuna que comprende un inmunoestimulante un antigeno y una sal metalica y uso de dicha composicion para preparar un medicamento.composicion de vacuna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |